Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Henry Trattler

Ophthalmology Miami, FL Medical Doctor

NPI 1184649170 CMS profile 280031

900 Nw 17Th Ave, Miami, FL 33101

Open in the dashboard

General payments

$8,338

251 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Henry Trattler of Miami, FL is reported in the CMS Open Payments database as having received $8,338 across 251 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $170 2
2024 General $1,331 37
2023 General $1,983 74
2022 General $1,820 69
2021 General $841 24
2020 General $696 19
2019 General $1,496 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Henry Trattler
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Henry Trattler were reported at $170. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Henry Trattler Ophthalmology median Middle half National median
2019 $1,496 $258 $104–$655 $163
2020 $696 $126 $45–$321 $114
2021 $841 $205 $76–$534 $132
2022 $1,820 $266 $100–$678 $149
2023 $1,983 $308 $117–$745 $160
2024 $1,331 $340 $127–$846 $164
2025 $170 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $874 30 payments
  2. Alcon Vision LLC $756 28 payments
  3. Sun Pharmaceutical Industries Inc. $642 11 payments
  4. Novartis Pharmaceuticals Corporation $543 27 payments
  5. Mallinckrodt Hospital Products Inc. $483 26 payments
  6. Allergan Inc. $377 8 payments
  7. Kala Pharmaceuticals, Inc. $375 8 payments
  8. AbbVie, Inc. $357 11 payments
  9. Horizon Therapeutics plc $353 8 payments
  10. Aerie Pharmaceuticals, Inc. $327 6 payments
  11. Other $3,251 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,230 248 payments
  2. Education $108 3 payments
Products named General payments · program years 2019–2025
  1. XIIDRA $636 30 payments
  2. VYZULTA $561 20 payments
  3. Cequa $531 10 payments
  4. ACTHAR $483 26 payments
  5. MIEBO $412 9 payments
  6. PROLENSA $382 17 payments
  7. INVELTYS $375 8 payments
  8. LOTEMAX SM $343 15 payments
  9. TEPEZZA $329 7 payments
  10. Simbrinza $329 15 payments
  11. Other $6,023 187 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Ophthalmology: 891

Drug cost

$6,237

Median for Ophthalmology: $68,233

Branded share of claims

100%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 12 $6,237

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OXERVATE
  • Dompe US, Inc. $148
$148 — —
MIEBO
  • Bausch & Lomb Americas Inc. $117
$117 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $100
$100 — —
VYZULTA
  • Bausch & Lomb Americas Inc. $70
$70 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record